Page last updated: 2024-11-04

temozolomide and Anorexia

temozolomide has been researched along with Anorexia in 3 studies

Anorexia: The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.

Research Excerpts

ExcerptRelevanceReference
" We performed a phase I study to determine the maximum tolerated dose and preliminary efficacy of pegylated nanoliposomal irinotecan (nal-IRI)+metronomic temozolomide (TMZ) in patients with recurrent glioblastoma."9.41Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial. ( Baekey, J; Carcieri, A; Cielo, D; Disano, D; Donnelly, J; Elinzano, H; MacKinnon, K; Mohler, A; Robison, J; Safran, H; Sturtevant, A; Toms, S; Vatketich, J; Wood, R, 2021)
"The efficacy and safety of temozolomide were evaluated in 32 patients with anaplastic astrocytoma at first relapse."9.12[Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study]. ( Aoki, T; Fujimaki, T; Hori, T; Ikeda, J; Kochi, M; Maruno, M; Matsutani, M; Nakamura, H; Nishikawa, R; Sato, S; Sawamura, Y; Shibui, S; Sugiyama, K; Takahashi, H; Takahashi, J; Wakabayashi, T, 2006)
"This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy."7.80Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. ( Bae, SH; Cho, SY; Kim, CY; Kim, TM; Kim, YH; Kim, YJ; Lee, MM; Lee, SH; Park, CK; Park, MJ, 2014)
" We performed a phase I study to determine the maximum tolerated dose and preliminary efficacy of pegylated nanoliposomal irinotecan (nal-IRI)+metronomic temozolomide (TMZ) in patients with recurrent glioblastoma."5.41Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial. ( Baekey, J; Carcieri, A; Cielo, D; Disano, D; Donnelly, J; Elinzano, H; MacKinnon, K; Mohler, A; Robison, J; Safran, H; Sturtevant, A; Toms, S; Vatketich, J; Wood, R, 2021)
"The efficacy and safety of temozolomide were evaluated in 32 patients with anaplastic astrocytoma at first relapse."5.12[Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study]. ( Aoki, T; Fujimaki, T; Hori, T; Ikeda, J; Kochi, M; Maruno, M; Matsutani, M; Nakamura, H; Nishikawa, R; Sato, S; Sawamura, Y; Shibui, S; Sugiyama, K; Takahashi, H; Takahashi, J; Wakabayashi, T, 2006)
"This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy."3.80Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. ( Bae, SH; Cho, SY; Kim, CY; Kim, TM; Kim, YH; Kim, YJ; Lee, MM; Lee, SH; Park, CK; Park, MJ, 2014)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Elinzano, H1
Toms, S1
Robison, J1
Mohler, A1
Carcieri, A1
Cielo, D1
Donnelly, J1
Disano, D1
Vatketich, J1
Baekey, J1
Sturtevant, A1
MacKinnon, K1
Wood, R1
Safran, H1
Bae, SH1
Park, MJ1
Lee, MM1
Kim, TM1
Lee, SH1
Cho, SY1
Kim, YH1
Kim, YJ1
Park, CK1
Kim, CY1
Nishikawa, R1
Shibui, S1
Maruno, M1
Sugiyama, K1
Sato, S1
Fujimaki, T1
Takahashi, H1
Wakabayashi, T1
Takahashi, J1
Kochi, M1
Nakamura, H1
Sawamura, Y1
Ikeda, J1
Hori, T1
Aoki, T1
Matsutani, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
BrUOG 329: Onivyde (Nanoliposomal Irinotecan) and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: A Phase IB/IIA Brown University Oncology Research Group Study[NCT03119064]Phase 1/Phase 212 participants (Actual)Interventional2017-11-30Terminated (stopped due to lack of response to study therapy)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Determination of Maximum Tolerated Dose (MTD)

To evaluate the maximum tolerated dose of nanoliposomal irinotecan with continuous low-dose temozolomide for patients with recurrent glioblastoma. (NCT03119064)
Timeframe: Every two weeks for 4 weeks

Interventionmg/m^2 (Number)
All Participants50

Response

"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT03119064)
Timeframe: Every 2 months on study treatment then very 3 months once treatment has stopped, until progression of disease up to 2 years.

,
Interventionparticipants (Number)
Partial ResponseProgressive Disease
Dose 118
Dose 212

Toxicities

Treatment emergent toxicities of nanoliposomal irinotecan with continuous low-dose temozolomide using CTCAE version 4.03, grades 2 through 4 (NCT03119064)
Timeframe: Baseline through 30 days post off study treatment

,
Interventionevents (Number)
NeutropeniaALT/ASTHypokalemiaHypophosphatemiaNauseaFatigueDiarrheaAnorexiaDehydrationUrticaria
Dose 10211120001
Dose 21110222220

Trials

2 trials available for temozolomide and Anorexia

ArticleYear
Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial.
    American journal of clinical oncology, 2021, 02-01, Volume: 44, Issue:2

    Topics: Administration, Metronomic; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; B

2021
[Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:9

    Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine;

2006

Other Studies

1 other study available for temozolomide and Anorexia

ArticleYear
Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.
    Journal of Korean medical science, 2014, Volume: 29, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents, Alkylating; Brain Neopl

2014